New meta-analysis demonstrates that access to the GeneSight test can significantly improve response and remission rates for patients with depression
A new meta-analysis of six prospective controlled studies found that access to the GeneSight Psychotropic test significantly improved response and remission rates for adults with major depressive disorder. The study included 3,532 unique adults who had at least one prior treatment failure.
SourceThe Motion Agency·JournalJournal of Clinical Psychopharmacology·TypeMeta-analysis·DateSep 3, 2025